GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

January 31, 2016

Study Completion Date

November 30, 2016

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

GP2013

1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)

BIOLOGICAL

MabThera

1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)

BIOLOGICAL

Rituxan

1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)

Trial Locations (57)

2143

Pest Megyei Flór Ferenc, Kistarcsa

16635

Altoona Center for Clinical Research, Duncansville

19610

Clinical Research Center of Reading LLC, Wyomissing

21502

Klein & Associates, Cumberland

21740

Klein & Associates, Hagerstown

28210

DJL Clinical Research PLLC, Charlotte

29406

Low Country Rheumatology, PA, Charleston

38305

West Tennessee Research Institute, Jackson

40504

Bluegrass Community Research, Inc., Lexington

68516

Physician Research Collaboration, LLC, Lincoln

73103

Health Research of Oklahoma, Oklahoma City

78232

Arthritis & Osteoporosis Center of South Texas, San Antonio

89128

Innovative Health Research, Las Vegas

90057

Miller Clinical Research, Los Angeles

98133

The Seattle Arthritis Center, Seattle

01605

Clinical Pharmacology Study Group, Worcester

Unknown

Regional Health Clinical Research, Rapid City

Investigative Site, Buenos Aires

Investigative Site, Innsbruck

Investigative Site, Vienna

Investigative site, Kortrijk

Investigative site, Merksem

Investigative Site, Curitiba

Investigative Site, Goiânia

Investigative Site, São Paulo

North Estonia Medical Centre Foundation, Tallinn

Investigative Site, Amiens

Investigative site, Cahors

Investigative Site, Corbeil-Essonnes

Investigative site, La Gaillarde

Investigative Site, Orléans

Investigative Site, Frankfurt

Investigative Site, Freiburg im Breisgau

Investigative Site, Göttingen

Investigative Site, Hildesheim

Investigative Site, Jena

Investigative Site, München

Investigative Site, Nuremberg

Investigative Site, Ratingen

Investigative Site, Regensburg

Investigative Site, Würzburg

Investigative site, Ajmer

Investigative Site, Bangalore

Investigative Site, Hyderabad

Investigative Site, Jaipur

Investigative Site, New Delhi

Investigative Site, Secunderabad

Investigative Site, Milan

Investigative site, Bucharest

Investigative site, Cluj-Napoca

Investigative Site, Madrid

Investigative Site, Mérida

Investigative site, Santiago de Compostela

Investigative Site, Seville

Investigative Site, Istanbul

Investigative Site, Izmir

H-2800

Megyei Csolnoky Ferenc Kórház Nonprofit Zrt., Veszprém

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Sandoz

INDUSTRY